JP2003513903A5 - - Google Patents

Download PDF

Info

Publication number
JP2003513903A5
JP2003513903A5 JP2001536117A JP2001536117A JP2003513903A5 JP 2003513903 A5 JP2003513903 A5 JP 2003513903A5 JP 2001536117 A JP2001536117 A JP 2001536117A JP 2001536117 A JP2001536117 A JP 2001536117A JP 2003513903 A5 JP2003513903 A5 JP 2003513903A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001536117A
Other languages
Japanese (ja)
Other versions
JP2003513903A (ja
Filing date
Publication date
Priority claimed from US09/531,472 external-priority patent/US6413533B1/en
Application filed filed Critical
Publication of JP2003513903A publication Critical patent/JP2003513903A/ja
Publication of JP2003513903A5 publication Critical patent/JP2003513903A5/ja
Pending legal-status Critical Current

Links

JP2001536117A 1999-11-08 2000-11-08 前立腺癌の予防的化学療法 Pending JP2003513903A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US43620899A 1999-11-08 1999-11-08
US09/436,208 1999-11-08
US09/531,472 US6413533B1 (en) 1998-05-07 2000-03-20 Method for chemoprevention of prostate cancer
US09/531,472 2000-03-20
PCT/US2000/030658 WO2001034117A1 (en) 1999-11-08 2000-11-08 A method for chemoprevention of prostate cancer

Publications (2)

Publication Number Publication Date
JP2003513903A JP2003513903A (ja) 2003-04-15
JP2003513903A5 true JP2003513903A5 (enExample) 2005-12-22

Family

ID=27030854

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001536117A Pending JP2003513903A (ja) 1999-11-08 2000-11-08 前立腺癌の予防的化学療法

Country Status (19)

Country Link
US (1) US6413533B1 (enExample)
EP (1) EP1229903A4 (enExample)
JP (1) JP2003513903A (enExample)
KR (2) KR100793721B1 (enExample)
CN (1) CN1331463C (enExample)
AU (1) AU782444B2 (enExample)
BG (1) BG65794B1 (enExample)
CA (1) CA2390295C (enExample)
CZ (1) CZ20021763A3 (enExample)
HR (1) HRP20020422A2 (enExample)
HU (1) HUP0203304A3 (enExample)
IL (1) IL149545A0 (enExample)
IS (1) IS6375A (enExample)
MX (1) MXPA02004676A (enExample)
NO (1) NO20022221L (enExample)
PL (1) PL354726A1 (enExample)
SK (1) SK8162002A3 (enExample)
WO (1) WO2001034117A1 (enExample)
YU (1) YU43002A (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20040186185A1 (en) * 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20030130316A1 (en) * 2000-03-20 2003-07-10 Steiner Mitchell S. Method for chemoprevention of prostate cancer
US7737185B2 (en) 2001-07-09 2010-06-15 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
CA2453337C (en) 2001-07-09 2012-08-28 Zonagen, Inc. Methods and materials for the treatment of testosterone deficiency in men
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20040213841A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S Methods for treating hot flashes and gynecomastia
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20040096510A1 (en) * 2001-11-29 2004-05-20 Steiner Mitchell S. Prevention and treatment of androgen-deprivation induced osteoporosis
US7524866B2 (en) * 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
HRP20040547A2 (en) 2001-11-29 2005-08-31 Gtx Inc. Prevention and treatment of androgen-deprivation induced osteoporosis
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
KR20030061474A (ko) * 2002-01-14 2003-07-22 한미약품 주식회사 서트랄린 제조용 중간체로서 사용되는 시스-라세메이트화합물의 개선된 제조방법
FI114917B (fi) * 2002-08-29 2005-01-31 Hormos Nutraceutical Oy Ltd Lignaanikomplekseja
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US7483554B2 (en) * 2003-11-17 2009-01-27 Aureon Laboratories, Inc. Pathological tissue mapping
US7467119B2 (en) * 2003-07-21 2008-12-16 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
US7461048B2 (en) * 2003-07-21 2008-12-02 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
US7070816B2 (en) * 2003-12-05 2006-07-04 New Chapter, Inc. Methods for treating prostatic intraepithelial neoplasia with herbal compositions
WO2005086068A2 (en) * 2004-02-27 2005-09-15 Aureon Laboratories, Inc. Methods and systems for predicting occurrence of an event
MX2007000050A (es) * 2004-07-14 2007-07-10 Repros Therapeutics Inc Trans-clomifeno para el tratamiento de hipertrofia de prostata benigna, cancer de prostata, hipogonadismo, trigliceridos elevados y colesterol elevado.
NZ560551A (en) 2005-03-22 2010-02-26 Repros Therapeutics Inc Dosing regimes for trans-clomiphene
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
KR101505884B1 (ko) * 2006-05-22 2015-03-25 호르모스 메디칼 리미티드 만성 비세균성 전립선염 치료용 선택적 에스트로겐 수용체 조절제 또는 아로마타아제 저해제
US9301987B2 (en) * 2007-09-24 2016-04-05 Laila Nutraceuticals Anti-adipogenic compositions containing Piper betle and Dolichos biflorus
ES2718912T3 (es) 2007-10-16 2019-07-05 Repros Therapeutics Inc Trans-clomifeno para el tratamiento de la diabetes en hombres hipogonadales
EP2616078B1 (en) 2010-09-16 2019-12-25 Shimoda Biotech (Pty) Ltd Fulvestrant compositions and methods of use
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
CN104994877A (zh) 2012-11-02 2015-10-21 利普生物药剂公司 用于癌症治疗的反式-克罗米芬

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329364A (en) 1974-09-11 1982-05-11 Schering Corporation Antiandrogenic agents and methods for the treatment of androgen dependent disease states
US4474813A (en) 1980-10-24 1984-10-02 Schering Corporation Pharmaceutical preparations comprising flutamide
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
GB2126576B (en) 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
FI77839C (fi) 1982-05-27 1989-05-10 Farmos Oy Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat.
US5491173A (en) * 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
US5595985A (en) 1989-03-10 1997-01-21 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
US4990538A (en) 1989-08-23 1991-02-05 Harris Adrian L Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs
GB9126209D0 (en) * 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
JP3566741B2 (ja) * 1992-10-27 2004-09-15 日本化薬株式会社 自己免疫疾患治療薬
WO1994012162A1 (en) 1992-12-01 1994-06-09 Waerri Anni Maija Syndecan stimulation of cellular differentiation
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
DE69435137D1 (de) 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
EP0726772B1 (en) 1993-08-09 2001-11-07 Edward Baral A method for sensitization of cancer cells for killer cell mediated lysis
US5972383A (en) * 1994-03-02 1999-10-26 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
CA2143263C (en) * 1994-03-02 2002-01-08 Kerry John Hartauer Orally administrable raloxifene formulations
US5811120A (en) * 1994-03-02 1998-09-22 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5650425A (en) * 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
US5441986A (en) * 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
US5821254A (en) * 1995-02-17 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer
US5629007A (en) 1995-03-21 1997-05-13 Eli Lilly And Company Method of preventing prostatic cancer development
US5635197A (en) 1995-03-21 1997-06-03 Eli Lilly And Company Treatment and prevention of prostatic cancer metastasis
DE19526146A1 (de) * 1995-07-07 1997-01-09 Schering Ag Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
US5728707A (en) * 1995-07-21 1998-03-17 Constantia Gruppe Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
US5883118A (en) * 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
US5726202A (en) * 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
US5859045A (en) * 1996-05-08 1999-01-12 Novo Nordisk A/S Novo Alle Crystalline -! 3R 4R-trans-7 methoxy 2,2-dimethyl1-3-phenyl 1-4 4-12 pyrrolidin-1 -Y1!ethoxyl 1!chromane hydrogen fumarate
CA2255615C (en) * 1996-05-22 2006-08-29 Neuromedica, Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and docetaxel
ZA982819B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators.
ZA984650B (en) 1997-06-19 1998-12-08 Orion Corp Intratumoral administration of triphenylethylenes for the treatment of cancer
ATE411016T1 (de) * 1997-08-15 2008-10-15 Univ Duke Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten
GB9805868D0 (en) * 1998-03-20 1998-05-13 Zeneca Ltd Anti-tumour agents
SK16642000A3 (sk) * 1998-05-07 2002-08-06 The University Of Tennessee Research Corporation Spôsob chemoprevencie rakoviny prostaty
CA2346333A1 (en) * 1998-10-06 2000-04-13 Usda-Ars-Ott Compositions and methods of inhibiting neoplastic diseases with compounds related to limocitrin and 5-desmethyl sinensetin

Similar Documents

Publication Publication Date Title
BE2014C009I2 (enExample)
BE2013C060I2 (enExample)
BE2013C048I2 (enExample)
BE2012C026I2 (enExample)
BE2012C016I2 (enExample)
BRPI0113085B8 (enExample)
BRPI0112928B8 (enExample)
BE2011C041I2 (enExample)
AR028236A3 (enExample)
BE2010C040I2 (enExample)
JP2003530524A5 (enExample)
BRPI0113372A8 (enExample)
BR0112866A2 (enExample)
CN300955183S (zh) 连接件
CN3135584S (enExample)
CN3138718S (enExample)
CL2001002979A1 (enExample)
AU2000271150A8 (enExample)
CN3133795S (enExample)
CN3134542S (enExample)
CN3135488S (enExample)
CN3135489S (enExample)
CN3135513S (enExample)
CN3145763S (enExample)
CN3135640S (enExample)